EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence... (o extendover the next 3 years. EpiStem i...)

EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme

Date:9/19/2007

o extend over the next 3 years. EpiStem is also now working to gain GLP compliance for the next phase of the project, in order to help the consortium develop drugs for FDA approval in future years".

Other members of the Consortium include the University of Maryland, Baltimore, the University of Illinois at Chicago, Indiana University at Indianapolis, the Armed Forces Radiobiology Research Institute at Bethesda, Fast Track Drugs and Biologics LLC, Aotech, LLC, and Information Management Consultants, Inc.

Additional Information

EpiStem is a biotechnology company commercialising adult stem cells in the areas of oncology and gastrointestinal diseases as well as cosmeceutical applications. EpiStem develops innovative therapeutics and diagnostic biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. EpiStem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.

EpiStem operates two distinct business divisions, Contract Research Services and Novel Therapies.

Contract Research Services

Contract Research Services provides specialised preclinical efficacy testing primarily for drug development companies on a fee for service basis. This division on a standalone basis is cash generative and profitable with a five-year track record of providing testing services to over 72 international company clients primarily in Europe and the United States.

Novel Therapies

Novel Therapies is focused on developing its own innovative therapeutics and diagnostic biomarkers. Through its discovery platform, Novel Therapies has identified 250 potential drug candidates, of which a subset will undergo further evaluation as stem cell regulators for the Group's emerging drug development pipeline. Novel Thera
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. National Instruments DIAdem -- Complete Your Technical Data Management Framework with Powerful Off-line Analysis, Visualization, and Report Generation
2. Potawatomis complete acquisition of tech firm
3. Sonic Foundry completes $11.25M stock offer
4. Orion Energy completes $5M capital round
5. RedPrairie completes MARC acquisition
6. Metavante completes purchase of check processing firm
7. GE completes $1.2 billion acquisition
8. M & Is Metavante completes Brasfield Corp. acquisition
9. Berbee Data Centers complete audit, certification
10. Metavante completes GHR Systems acquisition
11. Metavante completes TREEV acquisition

Post Your Comments:

EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence...(o extendover the next 3 years. EpiStem i...)